HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy
HCB101 clinical validation anchors FBDB™ platform expansion, global partnering, and international capital markets strategy
[Taipei, Shanghai, San Francisco | September 8, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.
HanchorBio Chief Financial Officer Mu-Tseng Tseng presented the Company’s strategy to build on the clinical validation of HCB101, expand its proprietary FBDB™ multifunctional biologics platform, advance global partnering opportunities, and broaden the Company’s engagement with international capital markets.
Global Biotechnology Market Rebounds as Capital Increasingly Focuses on Clinical Validation and Partnership Value
Global biotechnology markets have strengthened over the past year, while licensing and strategic partnership activity has remained active. According to Goldman Sachs research, as of the end of July 2026, the NYSE Arca Biotechnology Index and Nasdaq Biotechnology Index had generated approximately 50% and 46% returns, respectively, over the preceding 12 months. Separately, data from J.P. Morgan and DealForma indicated that global biopharmaceutical licensing transactions reached approximately US$82.7 billion in the first quarter of 2026.
Tseng noted that investor and strategic interest is increasingly concentrated on companies with differentiated science, human clinical validation, clear development pathways, and global partnering potential.
HCB101 Anchors Clinical Development
HCB101, HanchorBio’s proprietary SIRPα-Fc fusion protein targeting the SIRPα-CD47 immune checkpoint, serves as the Company’s lead clinical anchor and is being developed as a potential macrophage-directed immunotherapy backbone for combination treatment.
Second-line gastric/gastroesophageal junction (GC/GEJ) cancer remains a key development priority. In previously disclosed early clinical data, HCB101 combination therapy at clinically relevant dose levels demonstrated an 80% objective response rate (ORR) and 100% disease control rate (DCR) in second-line GC/GEJ cancer.
HanchorBio is also evaluating HCB101 across colorectal cancer, head and neck cancer and other tumor types as it seeks to establish the broader potential of macrophage-directed immunotherapy across multiple standard-of-care combination strategies.
“Clinical progress remains our most important value driver,” said Tseng. “Our strategy is to establish HCB101 as a strong clinical anchor, expand the biology through our FBDB™ platform, and create multiple paths for value through internal development and global partnerships.”
According to IQVIA market analysis, the global market associated with second-line GC/GEJ cancer and second-line colorectal cancer are projected to reach approximately US$709 million and US$3.5 billion, respectively, by 2036, highlighting the potential opportunity as HCB101 development expands across indications.
Expanding from Clinical Anchor to Platform
Clinical and translational learnings from HCB101 are informing the continued expansion of HanchorBio’s FBDB™ platform.
The Company is advancing a portfolio that includes HCB301, a trispecific SIRPα/PD-L1/TGF-β fusion protein; HCB303, a next-generation trispecific program integrating SIRPα/CD47, PD-L1/PD-1 and TIGIT/PVR biology; and HCB206, a CD20 × SIRPα program extending macrophage-directed biology beyond oncology into immune-mediated diseases.
Together, these programs reflect HanchorBio’s strategy of moving from a single clinical anchor toward a broader portfolio of multifunctional biologics designed to coordinate innate and adaptive immunity.
Global Partnering and Capital Markets Strategy
HanchorBio continues to advance business development alongside its internal R&D programs. During the first half of 2026, the Company held face-to-face discussions with more than 20 global pharmaceutical companies regarding HCB101, while additional partnering discussions have continued across HCB301 and HCB206.
Following HanchorBio’s listing on the Taiwan Innovation Board in May 2026, the Company’s Board of Directors also approved a proposal for a potential American Depositary Receipt (ADR) offering, subject to shareholder and regulatory approvals.
The proposed ADR program is intended to broaden HanchorBio’s access to international biotechnology and healthcare investors and strengthen the Company’s connectivity with global capital markets as its clinical pipeline advances.
Focused on the Next 3 to 12 Months
Over the next 3 to 12 months, HanchorBio expects to remain focused on key value-driving milestones across clinical development, pipeline expansion, international licensing, and strategic collaborations.
Building on the clinical foundation established by HCB101, the Company aims to translate clinical validation into broader platform value across oncology and immune-mediated diseases while continuing to expand its global development, partnering and capital markets presence.
About HanchorBio
HanchorBio, Inc. (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB™ platform. By integrating complementary innate and adaptive immune mechanisms with differentiated biologic architectures, HanchorBio is advancing a pipeline of therapies designed to address treatment resistance in oncology and immune-mediated diseases.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategies, partnering activities, capital markets plans, and future development. Actual results may differ materially from those expressed or implied due to clinical development outcomes, regulatory review decisions, market conditions, and other risks and uncertainties. Except as required by applicable law, HanchorBio undertakes no obligation to update any forward-looking statements.